The nature of the cooperation between platelets and tumor cells during the process of blood-borne metastasis is essentially unknown. In previous in vitro studies we showed that platelets participated in the formation of gaps in the endothelial cell lining, and that concomitantly heparan sulfate glycosaminoglycans were degraded by the platelet heparitinase, released on activation of platelets. In the current study we show that the ability t o degrade proteoheparan sulfate derived from endothelial extracellular matrix is gradually eliminated when the number of human platelets is decreased from 5 x I O 7 to 10' cells/mL. When aliquots of conditioned media or lysates of either Eb or heat-inactivated ESb mouse lymphoma cells (both of which showed no heparanase activity) were added t o freeze-thawed lysates of 10' platelets, a reappearance of platelet heparitinase activity was observed. A similar activation was not elicited by lysates of several normal mammalian cells. These data suggest that in its native form, a fraction of the platelet heparitinase is ECENT PUBLICATIONS have demonstrated that R during the intravascular phase of blood-borne metastasis, tumor cells interact with platelets to produce mural microthrombi at the sites of tumor cell extravasation through the capillary ~a 1 l . l '~ The relevance of platelettumor cell interactions to the metastatic process in vivo has been demonstrated in rodents by the reduction of pulmonary metastases from intravenous injections of tumor cells after induction of experimental immune thrombocytopenia:.' or in animals treated with the monoclonal antibody (MoAb) 10E5, which inhibits binding of platelets to tumor cells.8 In these experimental models the number of lung metastases could be restored to control levels by platelet transfusions.sr638 Morphologic and electron microscopy studies in vivo have suggested that the initial entrapment of metastatic tumor cells by the capillary endothelium is platelet independent.7s9x'0 However, shortly after entrapment, platelet aggregation is initiated in the capillary segment occupied by the tumor cell, and the platelets most adjacent to the tumor cells show evidence of activation and degran~lation.~*~-'~ This process is accompanied by breaching and widening of the adjacent endothelial to endothelial cell junction~,'~~~'~ characterized by retraction of the endothelial cells and exposure of the underlying basement memb~ane.'~'' Within several hours the platelet thrombi spontaneously dissolve, leaving the endothelial junctional gaps wide open, and the tumor cells are seen adherent to the exposed basement membrane and involved in its degradation in preparation for transmembrane migration."-14 A similar process of endothelial cell gap formation by platelets leading to adherence of tumor cells to the exposed basement membrane has been described in vitro,'5316 morphologically consistent with the in vivo observations. These studies also showed that heparan sulfate is concomitantly degraded by platelet heparitinase, suggesting that this enzyme may play a role in the process of gap formation during the extravasation of blood-borne Platelet heparitinase is a lysosomal endo-P-D-glucuronistored in an inactive form that can be activated by a factor secreted by lymphoma, but not by normal cells. Partial characterization of the heparitinase-activating factor showed that it is a heat-stable polyanionic molecule, devoid of proteolytic activity and resistant t o both proteolytic and chondroitinase digestions. Activation of platelet heparitinase was also observed on coincubation with chondroitinases ABC and AC, suggesting that the inactive form of platelet heparitinase could result from a complex formation with a chondroitinase-sensitive proteoglycan. The lymphoma-derived heparitinase activating factor itself is, however, not a chondroitinase, because activity of chondroitinase could not be detected in Eb and ESb cells. A possible mechanism by which tumor cells recruit and regulate the activity of platelet heparitinase, and its relevance t o the progression of blood borne metastasis, is discussed. @ I 1991 by The American Society of Hematology.
The nature of the cooperation between platelets and tumor cells during the process of blood-borne metastasis is essentially unknown. In previous in vitro studies we showed that platelets participated in the formation of gaps in the endothelial cell lining, and that concomitantly heparan sulfate glycosaminoglycans were degraded by the platelet heparitinase, released on activation of platelets. In the current study we show that the ability t o degrade proteoheparan sulfate derived from endothelial extracellular matrix is gradually eliminated when the number of human platelets is decreased from 5 x I O 7 to 10' cells/mL. When aliquots of conditioned media or lysates of either Eb or heat-inactivated ESb mouse lymphoma cells (both of which showed no heparanase activity) were added t o freeze-thawed lysates of 10' platelets, a reappearance of platelet heparitinase activity was observed. A similar activation was not elicited by lysates of several normal mammalian cells. These data suggest that in its native form, a fraction of the platelet heparitinase is ECENT PUBLICATIONS have demonstrated that R during the intravascular phase of blood-borne metastasis, tumor cells interact with platelets to produce mural microthrombi at the sites of tumor cell extravasation through the capillary ~a 1 l . l '~ The relevance of platelettumor cell interactions to the metastatic process in vivo has been demonstrated in rodents by the reduction of pulmonary metastases from intravenous injections of tumor cells after induction of experimental immune thrombocytopenia:.' or in animals treated with the monoclonal antibody (MoAb) 10E5, which inhibits binding of platelets to tumor cells. 8 In these experimental models the number of lung metastases could be restored to control levels by platelet transfusions.sr638 Morphologic and electron microscopy studies in vivo have suggested that the initial entrapment of metastatic tumor cells by the capillary endothelium is platelet independent.7s9x'0 However, shortly after entrapment, platelet aggregation is initiated in the capillary segment occupied by the tumor cell, and the platelets most adjacent to the tumor cells show evidence of activation and degran~lation.~*~-'~ This process is accompanied by breaching and widening of the adjacent endothelial to endothelial cell junction~,'~~~'~ characterized by retraction of the endothelial cells and exposure of the underlying basement memb~ane.'~'' Within several hours the platelet thrombi spontaneously dissolve, leaving the endothelial junctional gaps wide open, and the tumor cells are seen adherent to the exposed basement membrane and involved in its degradation in preparation for transmembrane migration."-14 A similar process of endothelial cell gap formation by platelets leading to adherence of tumor cells to the exposed basement membrane has been described in vitro,'5316 morphologically consistent with the in vivo observations. These studies also showed that heparan sulfate is concomitantly degraded by platelet heparitinase, suggesting that this enzyme may play a role in the process of gap formation during the extravasation of blood-borne Platelet heparitinase is a lysosomal endo-P-D-glucuroni- Although involvement in tumor metastasis has been suggested,15.16 its accurate role in platelet physiology has not been assessed. In the present study, we report that human platelets contain an enzymatically inactive form of heparitinase, which can be activated by soluble factor(s) secreted by tumor cells. This represents a new aspect of platelet-tumor cell interaction that may be of relevance to the regulation and progression of blood borne metastasis in vivo.
MATERIALS AND METHODS

Materials.
Fibroblast growth factor (FGF) was partially purified from bovine brain as described.u Dulbecco's modified Eagle's medium, RPMI 1640 medium, calf serum, fetal calf serum (FCS), penicillin, streptomycin, and trypsinEDTA solution were obtained from Grand Island Biological Co (Grand Island, NY). Tissue culture dishes were obtained from Falcon Labware Division, Becton Dickinson CO (Oxnard, CA), and from NUNC InterMed (Newbury Park, CA). Soybean trypsin inhibitor, trypsin, papain, thrombin, phenylmethyl sulfonyl flouride (PMSF), aprotinin, diisopropyl fluorophosphate (DFP), a-iodoacetamide (IAA), cetyl piridinium chloride (CPC), Triton X-100, and dextran T-40 were obtained from Sigma Chemical Company (St Louis, MO). Na, "SO, (450 to 600 mciimmol) was purchased from New England Nuclear (Boston, MA). Scintillation fluid, Scinti Verse BD, was purchased from Fisher Scientific (Springfield, NJ). Sepharose 6B and 2B was obtained from Pharmacia Fine Chemicals (Uppsala, Sweden). Chondroitinase ABC, chondroitinase AC, chondroitin-6-sulfate (CH,S), dermatan sulfate (DS), and keratan sulfate (KS) were purchased from Miles Scientific (Naperville, IL). All other chemicals were of reagent grade obtained from Sigma Chemical Company.
Preparation of gel-filtered platelet (GFP) lysates and thrombinactivated GFP supematants. GFP were prepared as described by Agam et al. 23 Lysates of GFP were prepared by subjecting 2 x lo8 GFP in 1 mL Tyrode buffer to 3 cycles of freeze (liquid nitrogen) and thaw (37°C). The lysates were aliquoted and stored at -20°C until used. For preparation of supernatants, GFP (1 to 5 x lo7 suspended in 1 mL Tyrode buffer, pH 7.4) were incubated with 2.0 U/mL bovine thrombin at 37°C for 10 minutes. The incubation mixture was centrifuged at 1,200g for 10 minutes and the platelet supernatant was aliquoted and frozen at -20°C until used.
The tumor cell lines Eb and ESb were established from methylcholantrene induced T lymphoma in DBN2 mice.2 Twicecloned low metastatic Eb (clone 737) and its high metastatic variant ESb (clone 721) were established by limiting and used in the present study. The cells were cultured in RPMI 1640 supplemented with glutamine (5 mmol/L), 2-mercaptoethanol (5 x molk), streptomycin (100 p,g/mL), penicillin (lOOUimL), and 10% FCS.
Cultures of bovine corneal endothelial cells were established from steer eyes as previously described?' Cells from stock cultures were dissociated with 0.05% trypsin/0.02% EDTA in phosphatebuffered saline (PBS) and subcultured at a split ratio of 1:lO in 16-mm wells of 4-well tissue culture plates (NUNC, Roskilde, Denmark). The culture medium consisted of Dulbecco's Modified Eagle Medium (DMEM) (1 g glucoseL) supplemented with 10% bovine calf serum, 5% FCS, penicillin (50 U/mL), and streptomycin (50 pg/mL). The cells were grown at 37°C in a 10% CO, humidified incubator. Partially purified bovine brain bFGF (100 ng/mL) was added every other day until the culture was nearly confluent. After 10 to 12 days in culture the cells exhibited a massive secretion of an underlying extracellular matrix (ECM) in a polar fashion and similar in organization and macromolecular composition to naturally occurring subendothelial basement membranes."
Cultures of bovine aortic endothelial cells were obtained as previously described." Culture conditions were identical to those described for corneal endothelial cells, except for the omission of FCS.
Vascular or corneal endothelial cells were plated at an initial density of 5 x lo4 cellsil6 mm well of a 4-well plate and maintained as described previously except that 5% dextran T-40 was included in the growth medium. Na, 35S0, (450 to 600 mCi/mmol) was added (40 pCiimL)
Cells.
Preparation of sulfate-labeled ECM-coated dishes.
3 and 7 days after seeding, and the cultures were maintained with the label without further medium change. Five to 7 days after reaching confluence (10 to 12 days after seeding) the cell layer was dissolved by exposure to 0.5% Triton X-100 in PBS (voVvol) (10 minutes, 22°C). The remaining nuclei and cytoskeletons were removed by 2 to 3 minutes of exposure to 20 mmol/L NH40H in PBS, followed by four washes with PBS, leaving the underlying ECM intact and firmly attached to the entire tissue culture dish?6~z-30 Previous studieszJ2 demonstrated that 70% to 80% of the matrix-incorporated radioactivity was associated with heparan sulfate glycosaminoglycan chains.
Degradation of sulfate-labeled ECM proteoglycans by platelet heparitinase. The ability of GFP to degrade the ECM was determined as previously described.I6 Briefly, lo6 to 5 x lo7 GFP or the equivalent amounts of supernatants from thrombin-activated GFP were incubated (24 hours, 37T, pH 6.5) on top of sulfatelabeled ECM in a 10% CO, humidified incubator. The culture medium was then collected and centrifuged (10,OOQg 5 minutes) and the supernatant fraction applied for gel filtration on a Sepharose 6B column (0.7 x 35 cm) equilibrated with PBS containing 0.1% sodium azide. Fractions of 0.2 mLwere collected at a flow rate of 5 mWh, and counted for radioactivity using Scinti Verse BD scintillation fluid. The excluded volume (Vo) was marked by blue dextran and the total included volume (Vt) by phenol red. The latter was shown to comigrate with free '5S04=.28-'2 High Mr-labeled material, representing soluble proteoglycans, eluted from the column with Kav < 0.2, (Mr of approximately 5 x lo') and was defined as peak I proteoglycan material. Fragments of beparan sulfate glycosaminoglycan chains, degraded by platelet heparitinase, were eluted with Kav between 0.5 and 0.75 (Mr 5 x 103 to 1 x lo4) and were defined as peak I1 heparan sulfate degradation prod~cts.''~'~ Recovery of labeled material applied on the column ranged from 85% to 95% in different experiments. Each experiment was performed at least four times and differences in elution positions (kav values) were less than 10%.
Preparation of soluble high Mr sulfate-labeledproteoglycans (peak I material). Culture plates coated with sulfate-labeled ECM were treated overnight with 25 pg/mL trypsin in PBS at 37°C. This procedure was previously shown to release high Mr proteoglycans (peak I material) from the ECM." Trypsin activity was then inhibited by incubation with soybean trypsin inhibitor (200 pg/mL) at 37°C for 60 minutes. The incubation medium was collected and aliquots of 1 mL were applied for gel filtration on a P-60 column (0.7 x 35 cm) eluted with PBS. Fractions of 0.2 mL were collected at a rate of 5 mL/h and counted for radioactivity. Over 80% of the radioactivity was eluted as a broad peak next to Vo. These fractions, pooled and frozen, contained the high Mr soluble proteoglycans, similar to peak I material described previously. Samples of each preparation of soluble proteoglycans was tested for precipitation on GFA glass filters (Whatman, Maidstone, England) with a 1% solution of CPC in 0.05 m o m NaCl and with 10% Trichloroacetic acid (TCA). Radioactivity associated with the filters was determined by liquid scintillation c o~n t i n g .~~~ Degradation of soluble high Mr sulfate-labeled proteoglycans (peak I material) by platelet heparitinase. To test the ability of GFP to degrade soluble sulfate labeled proteoglycans (peak I material), lo6 to 5 x lo7 GFP, or the equivalent amounts of either GFP lysates or the supernatants from thrombin activated GFP, were incubated (24 hours, 37"C, pH 6.5) with 0.5 to 2 mL of sulfate-labeled soluble proteoglycans (approximately 20,000 cpm/mL) in a 10% CO, humidified incubator. At the end of incubation the tubes were the centrifuged (lO,OOOg, 5 minutes) and supernatant fractions were applied for gel filtration on Sepharose 6B columns, as described previously. Fragments of heparan sulfate degraded by platelet heparitinase were eluted as peak I1 material with Kav between 0.5
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RESULTS
Figure 1A
shows that incubation (24 hours, 37°C) of 5 x lo7 GFP on top of "S-labeled ECM (16-mm wells) resulted in the release of radioactively labeled degradation products into the medium. Of the total cpm incorporated in the ECM, only 50% to 60% were released into the medium in the form of degradation products, which separated on gel filtration on Sepharose 6B columns into high and the low Mr products. These ECM degradation products consisted of heparan sulfate residues, because 80% to 90% of the total radioactivity in the medium was precipitated with 0.05% cetyl piridinium chloride in 0.6 mol/L NaCl (data not shown), conditions that specifically precipitate heparan sulfate sequences?' Most of the labeled material in the medium was in the form of the low Mr (Kav = 0.67) heparan sulfate degradation products (peak 11), which accounted for approximately 70% of the released radioactivity ( Fig 1A) . The sum of the highest three values of radioactivity in peak I1 (fractions 22 through 24) was defined in subsequent experiments as an index for heparitinase activity. At this concentration of GFP, approximately 25% of the released radioactivity was in the form of high Mr soluble proteoglycans that eluted next to Vo (fractions 4 through 13, peak I) (Fig 1A) . The sum of the highest three values of radioactivity in peak I (fractions 6 through 8) was defined in subsequent experiments as an index for soluble proteoglycans not degraded by heparitinase. When the number of GFP was decreased by serial dilutions, there was a gradual decrease in the amount of peak I1 counts with a concomitant increase of peak I counts. When only lo6 platelets were used, the expression of heparitinase activity was abolished, and more than 90% of the released radioactivity was accounted by peak I soluble proteoglycans (Fig
Evaluation of heparitinase activity in GFP.
I A 1A). The effect of heparitinase was also detected when instead of intact GFP either the supernatant fraction of thrombin-activated GFP or freeze-thaw lysates of GFP were used, and instead of solid-phase proteoglycans in the form of intact ECM soluble peak I proteoglycans, isolated from trypsin-digested ECM served as substrate (Fig 1B) . The combination of GFP lysates and soluble peak I proteoglycans was used in subsequent experiments as the routine system for evaluations of heparitinase activity.
Activation ofplatelet heparitinase by Eb and ESb lymphoma cell lysates. Figure 2 shows that when lysates from lo6 GFP, which by themselves did not exhibit heparitinase activity, were incubated with lo6 Eb lymphoma cells (Fig  2A) , aliquots from conditioned media of Eb cultures (Fig  2B) , or lysates of lo6 Eb cells (Fig 2C) , it resulted in appearance of heparitinase activity, detected by accumulation of peak I1 low Mr heparan sulfate degradation products in the medium. Similar effects were observed when solid-phase (Fig 2, A and B) or soluble peak I proteoglycans ( Fig 2C) were used as substrates, and regardless of the incubation time with the substrate (6, 12, or 24 hours) (data not shown). The same degradation pattern of the sulfated proteoglycan substrate was observed when GFP and Eb cells were preincubated (1 hour, 37°C) before the labeled substrate was added (data not shown). Because the control experiments, as well as our previously published showed that Eb cells do not express heparanase activity, the data suggest that Eb cells produce and secrete a soluble factor that activates an inactive form of platelet heparitinase in platelet lysates. Figure 2D shows that heparitinase activation was obtained also with the highly metastatic ESb lymphoma cells. We have previously shown that this cell line expresses heparanase a~tivity.".~~ However, Fig 2D shows products. #en such heat-inactivated ESb cell lysate was coincubated with lysates of lo6 GFP, it activated the latent form of platelet heparitinase (Fig 2D) in a pattern similar to that observed with Eb lysates. Heparitinase activation was also observed with heat-inactivated aliquots of conditioned media from ESb cell cultures (data not shown).
Partial characterization of the Eb-derived heparitinase activating fuctor(s).
To investigate the nature of the tumor cell-derived heparitinase activating factor(s), Eb lysates were subjected to various treatments and subsequently tested for their ability to activate GFP heparitinase. The activating factor was not precipitated by centrifugation of Eb lysates at 10,OOOg for 15 minutes, was not dialyzed through a dialysis bag with a cut-off pore size of 6,000 to 8,000 daltons, and was not affected by reduction of disulfide bonds with dithiothreitol (DTT). The activating factor retained 70% to 80% of its activity following a 30-minute incubation at 56"C, or 10-minute treatment at 70"C, but was inactivated when exposed to 100°C for 10 minutes ( Table   To evaluate the possibility that the activating factor is a protease, Eb lysates (equivalent of lo6 cells/mL) were incubated with ['HI-acetylated casein (40 &assay; 5 x lo' dpm/pg) under conditions identical to those applied in the 1)-measurements of heparan sulfate degradation (24 hours, 37°C). The protein was then precipitated with 5% cold TCA, centrifuged, and the supernatant was tested for radioactivity. Control experiments showed significant proteolytic activity in Eb lysates (data not shown), but 60% to 70% of this proteolytic activity was destroyed by heating to 56°C for 30 minutes, and it was totally abolished by heating to 70°C for 10 minutes. In contrast, such heat treatments had only a small effect on the Eb-mediated activation of the platelet heparitinase (Table 1) . Likewise, there was little or no effect of serine protease inhibitors (10 mmol/L DFP, or 5 mmol/L PMSF) on the Eb-mediated stimulation of the GFP heparitinase. A mixture of protease inhibitors, consisting of 10 mmol/L IAA, 0.3 U/mL aprotinin, and 200 p,g/mL soybean trypsin inhibitor (SBTI), which inhibited the casein proteolytic activity of Eb lysate by 50% to 60% (data not shown) and had no effect on the activation of GFP heparitinase by Eb cell lysate ( Table 1) .
The Eb-derived factor itself was found to be resistant to
proteolysis. Pretreatment of Eb lysates (equivalent of lo6
Eb cells) with 25 p.g/mL trypsin or 25 p.g/mL papain (30 minutes, 37°C) did not affect the capacity of the lysates to activate platelet heparitinase (Table 1) . Similarly, there was no effect to pretreatment of Eb lysate with partially purified A.
E.
C.
D.
E. The data summarized in this table represent data pooled from different experiments performed with different cell preparations and different batches on soluble proteoglycan substrates. The basic effect of Eb-derived factor(s) on platelet heparitinase is shown in (A) that serves as standard for comparison with the effects observed in the other panels. 35S-labeled soluble proteoglycans were incubated (24 hours, 37°C) with lysates of 10' GFP in the presence or absence of lo6 lysed Eb cells, and analyzed by gel filtration on Sepharose 68. The sum of the highest three values of cpm in peak II (fractions 22 through 24) was used as an index for heparitinase activity, whereas the amount of cpm in fractions 6 through 8 of peak I was used as an index for soluble proteoglycans not degraded by the platelet heparitinase. Within each experiment the difference in triplicate peak values did not exceed 215%, although when different experiments (as shown in the different panel) were compared the peak values differed within the range of *30%, depending on the batch soluble proteoglycan preparations used as substrate. (6) 37°C ) of Eb cell lysates with either 25 pg/mL trypsin followed by 200 pg/mL soybean trypsin inhibitor; 25 pg/mL papain followed by heating at 70°C for 10 minutes; 20 pg/mL heparanase partially purified from SK-hep-1 cells, followed by heating at 56°C for 30 minutes; or with 2 U/mL chondroitinase ABC, followed by incubation at 56°C for 30 minutes. (E) Preincubation (24 hours, 22°C) of Eb cell lysates with protamine-conjugated agarose beads (vol/vol), followed by centrifugation and incubation of the supernatant fraction with GFP lysates and peak I material.
Controls
heparanase (isolated from SK-Hep-I cells), chondroitinase D C , or chondroitinase AC (2 U/mL of either enzyme) ( Table 1) . In these experiments, the Eb lysates were initially incubated with the corresponding enzyme at 37°C for 24 hours, then heat-inactivated (HI) at 56°C for 45 minutes, and tested for heparitinase activation. In contrast, attempts to adsorb the Eb-derived factor on protamine-coated beads resulted in removal of its ability to induce platelet heparitinase activity. One milliliter of Eb cell lysate (derived from 4 X lo6 Eb cells) was incubated (voVvol) with protamine agarose beads (Sigma Chemical Co) for 120 minutes at room temperature, centrifuged, and the supernatant was collected and used for activation of platelet heparitinase. Table 1 shows that this procedure eliminated nearly completely the capacity of the Eb cell extracts to activate platelet heparitinase. The treatment with the protamine beads did not change the pH of the supernatants, which remained at 6.8, a pH that is optimal for heparitinase activity. Control incubations of the protamine beads with the buffer used for the lysis of GFP yielded supernatants that had no effect on heparitinase activity. These control experiments suggest that removal of the activating factor, rather than release of a heparitinase inhibitor from the protamine beads, was responsible for the observed effect of protamine. Table 2 demonstrates that lysates of lo6 cells from cultures of several types of normal mammalian cells (bovine aortic endothelial cells, human skin fibroblasts, murine peritoneal macrophages) incubated with lysates of lo6 GFP and with soluble peak I proteoglycans failed to activate platelet heparitinase, suggesting that the activating factor(s) identified in Eb and ESb cell lysates is preferentially expressed in tumor cells.
Effects of glycosaminoglycans and chondroitinases on q r e ssion of platelet heparitinase. Several of the controls in the experiments that tested the sensitivity of the Eb cell extracts to chondroitinase digestion (discussed previously) suggested that the chondroitinases themselves were capable of activating the platelet enzyme. Figure 3 shows that incubation (24 hours; 37°C) of chondroitinase ABC (2 U/mL) with lo6 GFP lysates and with soluble peak I proteoglycans, activated platelet heparitinase in a pattern similar to that observed with extracts of lo6 Eb cells. Chondroitinase AC (2 U/mL) also activated platelet heparitinase, although it was less active than chondroitinase AJ3C (data not shown). These data suggest that glycosaminoglycans, constitutively present in GFP lysates, may serve as the natural inhibitors of platelet heparitinase. To further evaluate this possibility, several glycosaminoglycans were incubated with lysates of lo7 GFP, and heparitinase activity was tested using soluble peak I proteoglycans used as substrate. This concentration of GFP lysate exhibited a significant platelet heparitinase activity ( Table 3 ; see also Fig 1B) . The addition of 10 p,g/mL %-labeled soluble proteoglycans were incubated with 10' lysed GFP in the absence or presence of lysates prepared from 10' Eb lymphoma cell, lo6 human skin fibroblasts, 10' bovine aortic endothelial cells (BAEC), or 10' murine peritoneal resting macrophages. For details of the experimental procedure, see the legend for (A) in Table 1 .
For of either CH,S, DS, or KS resulted in a complete inhibition of this platelet heparitinase activity (Table 3 ). The same amount of these glycosaminoglycans failed to inhibit the ESb tumor heparanase, while both the platelet and ESb enzymes were inhibited in the presence of 10 pg/mL of either heparin or heparan sulfate (data not shown). When 2 U/mL chondroitinase ABC was added to the incubation mixture after 24 hours pretreatment of GFP lysate with 10 kg/mL CH,S, there was complete restoration of the platelet heparitinase activity (Table 3) . A similar recovery of platelet heparitinase activity was observed after condroitinase ABC treatment of DS pretreated GFP extracts (data not shown).
DISCUSSION
Our data demonstrate that soluble factors secreted by tumor cells can affect the level of functional expression of Lysates of lo7 GFP were preincubated (2 hours, 37°C) with 10 pg/mL of either KS, DS. or CH,S. GFP lysates (10' platelets) were also preincubated (2 hours, 37°C) with CH,S followed by incubation (24 hours, 37°C) with sulfate-labeled peak I material and either 2 U/mL chondroitinase ABC or 10' lysed Eb cells. The incubation mixtures were then centrifuged and analyzed by gel filtration on Sepharose 68. The amount of cpm in fractions 22 through 29 of peak II is used as a measure for heparitinase activity, while cpm in fractions 6 through 8 represents the amount of peak I material not degraded by the platelet heparitinase.
the heparan sulfate degrading P-endoglucuronidase (platelet heparitinase) released on thrombin activation of human peripheral blood platelets. The synergistic effect was observed after incubation of platelets with either intact or lysed Eb and ESb lymphoma cells, or with their conditioned media, but not with lysates of several normal cells, such as bovine aortic endothelial cells, human skin fibroblasts, and nonactivated murine peritoneal macrophages. The data also suggest that a large proportion of the heparitinase released on thrombin activation or freeze-thawed lysis of platelets is in the form of a latent inactive enzyme, because after the basal enzymatic activity was eliminated by serial dilutions, there was still a significant inducible activity, detected by coincubation with Eb lymphoma cells. The mechanism by which the tumor cell-derived extracts activate platelet heparitinase remains unknown. The possibility that the activating factor is involved in the release of proteo-heparan sulfate from its solid-phase format in the ECM, thus providing a soluble substrate that is more amenable to enzymatic degradation, was ruled out by the experiments in which soluble peak I proteoglycans were used as substrate instead of the intact ECM. Both the solid-phase ECM-bound heparan sulfate and the soluble peak I proteoglycans served as equally sensitive substrates for the spontaneous and Eb-activated forms of the enzyme, suggesting that the addition of Eb cell lysates affected the expression levels of the heparitinase enzyme itself, rather than the format of its proteoglycan substrate. Our data also suggest that activation of the latent form of the enzyme by the Eb factor(s) is not a result of a proteolytic cleavage of a proenzyme, but is likely to be associated with removal of an inhibitor that inactivates the enzyme. This is supported by the experiment which demonstrates that the activating factor is heat stable, devoid of proteolytic activity, resistant to proteolytic digestion, and that its activity could be mimicked by incubation with chondroitinase ABC or AC. While coincubation of GFP lysates with chondroitinase ABC resulted in activation of the latent form of heparitinase, it nonetheless seems that the tumor cell-derived factor itself does not belong to the chondroitinase family of enzymes. This is supported by the high resistance of the Eb-derived factor to heat inactivation, and by the failure to demonstrate chondroitinase activity in the same Eb and ESb cells as used in our study. 33 The ability of chondroitinase ABC and AC to activate the latent form of platelet heparitinase suggests that the putative inhibitor is likely to contain a glycosaminoglycan residue. The facts that it is a polyanionic molecule and that its activity can be removed on incubation with protaminecoated beads are also consistent with the suggested glycosaminoglycan nature of the putative inhibitor. Whether the complex heparitinase-inhibitor is a natural configuration that represents the native form in which the enzyme is stored in platelet lysosomes, or whether it is an artifact of our experimental conditions is unknown. However, it should be noted that a recent study reported that platelet factor 4 (PF4) is released on platelet activation in the form of a proteoglycan-PF4 com~lex.3~ It has also been suggested, based on morphologic and other observations, that several For personal use only. on December 24, 2017. by guest www.bloodjournal.org From platelet basic proteins are stored in their native forms as complexes with platelet proteoglycans, with specific proteins associated with specific carrier prote~glycans.~~ In contrast to the platelet heparitinase, the activity of ESbderived tumor heparanase was not enhanced by coincubation with Eb cell extracts (data not shown). It suggests that the tumor-derived enzyme is not stored in the cell in the form of an inactive enzyme, consistent with the fact that the ESb cells themselves appeared to contain the heparitinaseactivating factor.
As to the mechanism by which Eb-and ESb-derived factors activate the latent enzyme, we suggest that the activating factor is probably capable of displacing the inhibitor from its complex formation with the enzyme. Despite the resistance of the Eb-derived factor to degradation by chondroitinase ABC and heparitinase, we still suggest that it could represent an unidentified form of a glycosaminoglycan. This hypothesis is consistent with its anionic nature, its resistance to proteolysis, and its remarkable resistance to heat inactivation, but the possibility that it is a lipid-based molecule should also be considered. A putative Eb-derived proteoglycan could activate the latent form of heparitinase by displacing the native inhibitory glycosaminoglycan due to superior binding affinity to the enzyme, thus either exposing the enzymatic active sites and/or inducing conformational changes that activate the enzyme. Efforts to isolate and characterize the Eb-derived factor(s) are currently underway.
The role of platelet heparitinase in the progression of the metastatic process is unknown. Morphologic and electron microscopy studies in vivo provide indirect evidence that platelets may be involved in the process of gap breaching in the capillary endothelium,' l3 an essential step in the sequence of events that lead to the transintimal migration of blood-borne cells. The formation of gaps requires partial detachment of adjacent endothelial cells from the underlying basement membrane. Anchorage of cells to basement membranes is mediated via focal adhesion p l a q~e s~~,~~ consisting of integrin receptors and species of cell surface proteoheparan ~u l f a t e~~.~' that bind to ECM-based adhesive m01ecules.~~~~~ The partial detachment of the endothelial cell from the underlying basement membrane during gap formation is, therefore, likely to require degradation of the cell membrane-associated type of heparan sulfate. Recent experiments have suggested that this species of heparan sulfate is distinct from the type that resides in basement membranes." Hennes et a133 have recently shown that tumor-type heparanase, which is distinct from platelet heparitinase," has substrate specificity for ECM-based heparan sulfate, but is incapable of degrading cell surfaceassociated heparan sulfate. The corresponding substrate specificities of platelet heparitinase is unknown, but we have previously shown that GFP are capable of producing wide open gaps in contact inhibited endothelial cell monolayers," thus suggesting that platelet heparitinase is perhaps capable of degrading the cell surface type of heparan sulfate. Furthermore, of the known heparan sulfate endo-p-D-glucuronidases, platelet heparitinase seems to exhibit the least requirements for substrate specificity, as it is capable of degrading both heparan sulfate and heparin m01ecules."~'~ The only prerequisite for substrate recognition by platelet heparitinase is the occurrence of N-sulfated groups,I7 which are abundant in all types of mammalian heparan ~ulfates.~' Therefore, we suggest the hypothesis that platelet heparitinase may play a critical role in the extravasation of malignant blood-borne cells by providing the tools for degradation of the cell membrane type of heparan sulfate an enzymatic activity that metastasizing cells apparently lack.
Therefore, our study proposes a novel hypothesis of the cooperation between tumor cells and platelets during the progression of blood-borne metastasis. Our data suggest that tumor cells are capable of not only recruiting platelet heparitinase by platelet activation, but can also control and regulate the activity of the platelet enzyme via their heparitinase activating factor(s). In addition to the inactive enzyme, our data also show that platelets secrete a spontaneously active form of the enzyme, which is independent of activation by tumor cell-derived factors. Whether these two activities represent two distinct isotypes of the enzyme, or whether the spontaneous activity results from the specific in vitro conditions of our experimental system is unknown.
Experiments are currently underway to further characterize the heparitinase activities released on activation of human platelets.
